Determining the Effectiveness of Addition of Drug Teneligliptin to Metformin, Glimepiride, Pioglitazone Combination in Type II Diabetic Patients
Diabetes is a widespread chronic disease that has spread to epidemic proportions in almost every developed and developing country. Diabetes is the leading cause of death in the world, affecting about 400 million people. Aims and Objectives: To investigate the efficacy of combining Teneligliptin with Metformin, Glimepiride, and Pioglitazone...
Read More
Study on the Development and Validation of Direct Spectrophotometric Method for the Estimation of Glimepiride
Developing simple, sensitive, and direct spectrophotometric methods for estimating the frequently prescribed antidiabetic hypoglycemia drug Glimepiride in pure and pharmaceutical dosage form. For the creation of procedures, the spectrophotometric methodology was used. For developed approaches, optimization of reaction parameters and spectral features is required. Propose a reaction mechanism for...
Read More
Determining the Efficacy and Safety of Teneligliptin and Metformin Versus Glimepiride and Metformin in Patients of Type-2 Diabetes Mellitus Uncontrolled with Monotherapy
Type 2 diabetes mellitus is one of the most common non-communicable diseases, with both short- and long-term effects. Material and Methods: The study included 60 patients, divided into two groups of 30 patients each. Teneligliptin 10 mg once a day and metformin 500 mg twice a day after meals...
Read More
The Improvement in Cardiovascular Risk Markers with Glimepiride in Pre-diabetic non-obese Subjects: Similar to Obese Cohort Treated with Metformin
Background: Over a 5- to 9-year period (mean, 7.20.2), we found that glimepiride was more effective than metformin in delaying the progression from pre-diabetes to type 2 diabetes in non-obese subjects. Metformin was the first-line treatment for newly diagnosed diabetics who were overweight. Furthermore, neither group experienced any deaths...
Read More